Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UZQBB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NOV0712-DXd
|
|||||
| Synonyms |
NOV0712 DXd
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo Co., Ltd.;
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.8
|
|||||
| Antibody Name |
Anti-CDH6 mAb NOV0712
|
Antibody Info | ||||
| Antigen Name |
Cadherin-6 (CDH6)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Deruxtecan
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 73.20% (Day 21) | Positive CDH6 expression (CDH6+++/++) | ||
| Method Description |
The CDH6-positive human ovarian tumor cell line PA-1 was subcutaneously inoculatedat a dose of 8,500,000 cells to the right flank region of eachfemale nude mouse (Day 0). On the day 11 of grouping, the antibody-drug conjugate NOV0712-DXd was intravenously administered at doses of 1 mg/kg to the tail of each mouse.
|
||||
| In Vivo Model | PA-1 CDX model | ||||
| In Vitro Model | Ovarian mixed germ cell tumor | PA-1 cells | CVCL_0479 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.12% (Day 21) | Positive CDH6 expression (CDH6+++/++) | ||
| Method Description |
The CDH6-positive human ovarian tumor cell line PA-1 was subcutaneously inoculatedat a dose of 8,500,000 cells to the right flank region of eachfemale nude mouse (Day 0). On the day 11 of grouping, the antibody-drug conjugate NOV0712-DXd was intravenously administered at doses of 3 mg/kg to the tail of each mouse.
|
||||
| In Vivo Model | PA-1 CDX model | ||||
| In Vitro Model | Ovarian mixed germ cell tumor | PA-1 cells | CVCL_0479 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.